Antibodies & Fusion Proteins
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
120
NCT05296772
Phase 1 First-in-human Study of JS014
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2022
Completion: Jan 31, 2025
NCT06092580
Phase 1 Study of AWT020 in Advanced Cancer
Start: Sep 15, 2023
Completion: Sep 30, 2026
Loading map...